BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
509 results:

  • 1. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and pd-l1 enhances antitumor responses.
    Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
    Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Expression of immune checkpoints pd-l1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
    Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
    Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Case report: Envafolimab causes local skin necrosis.
    Liu JJ; Xu XY; Han H; Wang T; Zhang W; Cui J; Semenov M
    Front Immunol; 2024; 15():1336311. PubMed ID: 38585260
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
    Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
    Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic colorectal cancer.
    Gherman A; Bolundut D; Ecea R; Balacescu L; Curcean S; Dina C; Balacescu O; Cainap C
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541123
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
    Levy A; Morel D; Texier M; Sun R; Durand-Labrunie J; Rodriguez-Ruiz ME; Racadot S; Supiot S; Magné N; Cyrille S; Louvel G; Massard C; Verlingue L; Bouquet F; Bustillos A; Bouarroudj L; Quevrin C; Clémenson C; Mondini M; Meziani L; Tselikas L; Bahleda R; Hollebecque A; Deutsch E
    Mol Cancer; 2024 Mar; 23(1):61. PubMed ID: 38519913
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Co-inhibition of TGF-β and pd-l1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistance.
    Nair R; Lannagan TRM; Jackstadt R; Andrusaite A; Cole J; Boyne C; Nibbs RJB; Sansom OJ; Milling S
    Oncoimmunology; 2024; 13(1):2330194. PubMed ID: 38516270
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
    Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
    Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer.
    Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
    Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Improved Immune Response for colorectal cancer Therapy Triggered by Multifunctional Nanocomposites with Self-Amplifying Antitumor Ferroptosis.
    Lin X; Chen H; Deng T; Cai B; Xia Y; Xie L; Wang H; Huang C
    ACS Appl Mater Interfaces; 2024 Mar; 16(11):13481-13495. PubMed ID: 38456402
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. TMEM160 promotes tumor immune evasion and radiotherapy resistance via pd-l1 binding in colorectal cancer.
    Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
    Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
    Pennel KAF; Hatthakarnkul P; Wood CS; Lian GY; Al-Badran SSF; Quinn JA; Legrini A; Inthagard J; Alexander PG; van Wyk H; Kurniawan A; Hashmi U; Gillespie MA; Mills M; Ammar A; Hay J; Andersen D; Nixon C; Rebus S; Chang DK; Kelly C; Harkin A; Graham J; Church D; Tomlinson I; Saunders M; Iveson T; Lannagan TRM; Jackstadt R; Maka N; Horgan PG; Roxburgh CSD; Sansom OJ; McMillan DC; Steele CW; Jamieson NB; Park JH; Roseweir AK; Edwards J
    J Exp Clin Cancer Res; 2024 Mar; 43(1):64. PubMed ID: 38424636
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.
    He R; Huang S; Lu J; Su L; Gao X; Chi H
    Front Immunol; 2024; 15():1362709. PubMed ID: 38415252
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. An innovative antibody fusion protein targeting pd-l1, VEGF and TGF-β with enhanced antitumor efficacies.
    Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
    Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and sipd-l1 for synergistic targeted cancer treatment.
    Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
    J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Progress of PD-1/pd-l1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
    Zhao S; Qiu Y; Yuan M; Wang Z
    Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer.
    Li H; Zheng N; Guo A; Tang W; Li M; Cao Y; Ma X; Cao H; Ma Y; Wang H; Zhao S
    Cell Death Dis; 2024 Feb; 15(2):107. PubMed ID: 38302412
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Novel immunotherapies for breast cancer: Focus on 2023 findings.
    Lan HR; Chen M; Yao SY; Chen JX; Jin KT
    Int Immunopharmacol; 2024 Feb; 128():111549. PubMed ID: 38266449
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 26.